Continuation of thiazolidinedione therapy in patients without left ventricular dysfunction who developed edema and congestive-heart-failure symptoms

American Journal of Health-System Pharmacy

Volumn 61, Issue 15, 2004, Pages 1604-1608

  Wang, Fei ^a,b,c   Vergara, Cunegundo ^d,e   Carabino, Jana ^a,f   Desilets, Alicia ^a,g   Vasquez, Ryan ^a,h  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b Adult Primary Care Center   (United States)

^c HARTFORD HOSPITAL   (United States)

^d HH ^*  (United States)

^e UC

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^g Bay Pines VA Medical Center   (United States)

^h KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ATORVASTATIN; CALCIUM; CELECOXIB; FLUOXETINE; FLUTICASONE PROPIONATE; FUROSEMIDE; GEMFIBROZIL; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN GLARGINE; IPRATROPIUM BROMIDE; ISOPHANE INSULIN; LANSOPRAZOLE; LEVOTHYROXINE SODIUM; LISINOPRIL; METFORMIN; NIZATIDINE; OLANZAPINE; PARACETAMOL; PIOGLITAZONE; ROSIGLITAZONE; SALBUTAMOL; SALBUTAMOL SULFATE; SALMETEROL XINAFOATE; SIMVASTATIN; SULFONYLUREA; UNINDEXED DRUG; 2,4 THIAZOLIDINEDIONE; 2,4-THIAZOLIDINEDIONE; ANTIDIABETIC AGENT; LIGAND;

ADULT; AGED; ANAMNESIS; ARTICLE; BODY WEIGHT; CASE REPORT; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES CONTROL; DOPPLER FLOWMETER; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; EDEMA; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART PALPITATION; HUMAN; HYPOGLYCEMIA; LUNG EDEMA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RISK ASSESSMENT; SYMPTOMATOLOGY; THORAX PAIN; THORAX RADIOGRAPHY; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; MIDDLE AGED;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPOGLYCEMIC AGENTS; LIGANDS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 7744243132     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.15.1604     Document Type: Article

References (14)

1. Thomas ML. Pulmonary edema associated with rosiglitazone and troglitazone. Ann Pharmacother. 2001; 35:123-4. Letter.
2. Hirsch IB, Kelly J, Cooper S. Pulmonary edema associated with troglitazone therapy. Arch Intern Med. 1999; 159:1811. Letter.
3. Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Pharmacotherapy. 2002; 22:924-9.
4. Wang F, Aleksunes L, Reagan L et al. Management of rosiglitazone-induced edema: two case reports and a review of the literature. Diabetes Technol Ther. 2002; 4:505-14.
5. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45.
6. Actos (pioglitazone hydrochloride) package insert. Lincolnshire, IL: Eli Lilly and Company; 2002.
7. Avandia (rosiglitazone maleate) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2002.
8. Hallakou S, Doare L, Foufelle F et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes. 1997; 46:1393-9.
9. Young MM, Squassante L, Werner J et al. Troglitazone has no effect on red cell mass or other erythropoietic parameters. Eur J Clin Pharmacol. 1999; 55:101-4.
10. Emoto M, Anno T, Sato Y et al. Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes. 2001; 50:1166-70.
11. Donnelly R, Gray S, Iskandar I. Rosiglita-zone and ankle swelling: an acute dose-dependent effect on endothelial permeability. Diabetes. 2001; 50(suppl 2):A68. Abstract.
12. Page RL, Gozansky WS, Ruscin JM. Possible heart failure exacerbation associated with rosiglitazone: case report and literature review. Pharmacotherapy. 2003; 23:945-54.
13. Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc. 2003; 78:1088-91.
14. Delea TE, Edelsberg JS, Hagiwara M et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes. A retrospective cohort study. Diabetes Care. 2003; 26:2983-9.